Search research articles
Contact Us
Filters
Showing results (171-180 of 174) with videos related to
Page
of 18
Sort By:
You have reached the last page of results.
This site can display upto 174 results.
Cancer Research
|
June 17, 2010
Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers
Kathryn G Roberts, Amanda M Smith, Fiona McDougall, et al.
Cancers
|
April 1, 2020
Tetraspanin CD9 is Regulated by miR-518f-5p and Functions in Breast Cell Migration and In Vivo Tumor Growth
Danielle R Bond, Richard Kahl, Joshua S Brzozowski, et al.
The Biochemical Journal
|
September 18, 2008
Identification of Tspan9 as a novel platelet tetraspanin and the collagen receptor GPVI as a component of tetraspanin microdomains
Majd B Protty, Nicholas A Watkins, Dario Colombo, et al.
Oncotarget
|
June 23, 2016
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors
Amanda M Smith, Matthew D Dun, Erwin M Lee, et al.
Page
of 18
Search research articles
Search
Showing results (171-180 of 174) with videos related to
Sort By:
Page
of 18
You have reached the last page of results.
This site can display upto 174 results.
Cancer Research
|
June 17, 2010
Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers
Kathryn G Roberts, Amanda M Smith, Fiona McDougall, et al.
Cancers
|
April 1, 2020
Tetraspanin CD9 is Regulated by miR-518f-5p and Functions in Breast Cell Migration and In Vivo Tumor Growth
Danielle R Bond, Richard Kahl, Joshua S Brzozowski, et al.
The Biochemical Journal
|
September 18, 2008
Identification of Tspan9 as a novel platelet tetraspanin and the collagen receptor GPVI as a component of tetraspanin microdomains
Majd B Protty, Nicholas A Watkins, Dario Colombo, et al.
Oncotarget
|
June 23, 2016
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors
Amanda M Smith, Matthew D Dun, Erwin M Lee, et al.
Page
of 18